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Summary
QUESTIONS UNDER STUDY: In Switzerland, the pre-
valence of medical end-of-life practices had been assessed
on a population level only once – in 2001 – until in 2013/14
an identical study was conducted. We aimed to compare the
results of the 2001 and 2013 studies with a special focus on
shared decision-making and patients' decision-making ca-
pacity.
METHODS: Our study encompassed a 21.3% sample of
deaths among residents of the German-speaking part of
Switzerland aged 1 year or older. From 4998 mailed ques-
tionnaires, 3173 (63.5%) were returned. All data were
weighted to adjust for age- and sex-specific differences in
response rates.
RESULTS: Cases with at least one reported end-of-life
practice significantly increased from 74.5% (2001) to
82.3% (2013) of all deaths eligible for an end-of-life de-
cision (p <0.001). In 51.2% there was a combination of at
least two different end-of-life decisions in one case.
In relation to discussion with patients or relatives and oth-
erwise expressed preferences of the patient, 76.5%
(74.5–78.4%) of all cases with reported medical end-of-life
practice in 2013 (2001: 74.4%) relied on shared decision-
making, varying from 79.8% (76.5–82.7%) among not at
all capable patients to 87.8% (85.0–90.2%) among fully
capable patients. In contrast to a generally increasing trend,
the prevalence of end-of-life practices discussed with fully
capable patients decreased from 79.0% (75.3–82.3%) in
2001 to 73.2% (69.6–76.0%) in 2013 (p = 0.037).
CONCLUSIONS: Despite a generally high incidence of
end-of-life practices in Switzerland, there remains potential
for further improvement in shared decision-making. Efforts
to motivate physicians to involve patients and relatives
may be a win-win situation.
Key words: alleviation of pain, assisted death, decision-
making capacity, end-of-life practice, forgoing life-
prolonging treatment, hastening death, patient's request,
shared decision-making
Introduction
Progress in medicine has greatly increased the ability to
prolong life and protract the dying process. These develop-
ments inevitably promote situations that require decision-
making on medical interventions that may hasten death
at the end of life, such as withholding potentially life-
sustaining treatments or even administering (potentially)
life-shortening drugs. Undisputedly, goals other than max-
imising life span have to guide medical decision-making
at the end of life, especially alleviation of suffering and
ensuring the best possible quality of life for the patients
and support for their family members [1]. An increasingly
balanced consideration of medical, ethical, psychological
and societal aspects [2] supports shared decision-making:
"Whenever possible, decisions on treatment and care
should be made jointly by the team responsible for care of
the patient and the family members" ([1], p.8).
Specific medical end-of-life decisions include: withholding
or withdrawing potentially life-prolonging treatment, alle-
viating pain or other symptoms with drugs in doses large
enough to hasten death as a possible or partly intended side
effect, and physician-assisted death (prescription or supply
of drugs to enable the patient to commit (assisted) suicide;
administration of drugs to end the patient's life on his/her
explicit request (euthanasia); ending life without the pa-
tient's explicit request [2].
Large-scale surveys to monitor medical end-of-life prac-
tices were conducted for the first time in the Netherlands in
1990/91 [3] and in Belgium in 1998 [4], accompanying the
upcoming discussion on euthanasia regulation. In 2001/02
medical end-of-life practices were assessed in six European
countries – the Netherlands, Belgium (Flanders), Denmark,
Sweden, Italy (Emilia-Romagna, Trento, Tuscany, Veneto)
and Switzerland (German-speaking part) [2]. Although
prevalences were periodically assessed since then in the
Netherlands and Belgium in order to monitor changes after
enactment of the respective laws [5, 6], in Switzerland the
2001 survey remained was not repeated for a long time.
Not before 2013/14 was an identical study conducted, with
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the first key results published only very recently in a brief
research letter [7].
In this paper, we aim to give a more detailed comparison
of the results of the Swiss 2001 and 2013 studies. Besides
prevalence figures, there is a special focus on the persons
involved in decision-making and the role of the patient's
decision-making capacity. There is now growing literature
about patients’ involvement in decision-making and shared
decisions in general; however, this is mostly limited to in-
tensive care or aggressive care settings [8, 9, 10] and there-
fore not generalisable to whole populations. With this study
we aimed to close some of these knowledge gaps.
Methods
Death certificate survey and questionnaire 2001
In principle, the Swiss medical end-of-life decisions sur-
veys of 2001 and 2013 had the same design and followed
the structure of the 2001 EURELD survey [2]. Between
September 2001 and February 2002, the Swiss Federal
Statistical Office drew, in five waves, a random sample of
all registered deaths of residents aged 1 year or older, oc-
curring between June 1 and October 30, 2001. The respect-
ive death-certifying physicians received a four-page self-
administered questionnaire and were asked to return it to
the Swiss Academy of Medical Sciences in Basel. If the
certifying physician was not the attending physician, he or
she was asked to pass the questionnaire to the attending
physician. Nonrespondents received at most two reminders
per death case (last shipment on April 2002). In total, 4991
questionnaires were mailed, of which 3355 (67%) were re-
turned.
The questionnaire consisted of prestructured questions de-
rived from a common English version that was translated
into the languages of the different EURELD regions and
translated back into English to check for inconsistencies.
Details of the questionnaire have been described elsewhere
[2, 11].
Death certificate survey 2013
Between August 7, 2013 and February 5, 2014, the Swiss
Federal Statistical Office drew weekly a random sample
of all deaths registered for residents aged 1 year or older
who had died not more than 180 days before registration.
On this basis and under conditions of strict anonymity, the
Epidemiology, Biostatistics and Prevention Institute of the
University of Zurich (EBPI; then Institute of Social and
Preventive Medicine) mailed a four-page questionnaire to
the respective death-certifying physician. If the certifying
physician was not the attending physician, he or she was
asked to pass the questionnaire to the attending physician.
Nonrespondents received at most two reminders per death
case (last shipment on April 15, 2014).
The attending physicians were requested to complete the
questionnaire and to return it to the Swiss Academy of
Medical Sciences (SAMS; then in Basel), where the re-
spective identifications (a four-digit number) were regu-
larly assessed and communicated to the EBPI. SAMS only
passed the filled-in questionnaires to the EBPI after the
EBPI had confirmed the clearing of names and addresses of
the physicians belonging to the respective ID, ensuring that
completed questionnaires could never be linked to a partic-
ular physician or patient.
Returning the questionnaire was regarded as implicit con-
sent of the physician to participate in the study. The study
was granted an official waiver for formal ethics committee
review by the Zurich Cantonal Ethics Board (KEK-StV-Nr.
23/13).
In total, a 21.3% sample of deaths of residents of the
German-speaking part of Switzerland was obtained and
4998 referring questionnaires were mailed. On June 11,
2014, the last completed questionnaire arrived at EBPI. In
sum, 3173 questionnaires (63.5%) were returned. Ques-
tionnaires were scanned and manually completed with
commentaries and notes arising from spontaneous physi-
cians' feedback by phone or correspondence until August
2014. From September to November 2014 all hand-written
commentaries and notes on the questionnaires were recor-
ded.
The sample of deaths was 41.1% in the French- and 62.9%
in the Italian-speaking parts of Switzerland (analysis in
progress). Sampling fractions were derived from deaths re-
gistered in the same season of the preceding year, with
the goal to reach a sample of 5000 questionnaires for the
German-, 3000 for the French- and 1000 for the Italian-
speaking part of the country.
Questionnaire 2013
The questionnaire was drawn up in the closest possible
accordance with the 2001 survey, i.e., the international
EURELD study [2] and previous death certificate studies
in the Netherlands [3]. This approach was also followed in
recent surveys in the Netherlands and Belgium [5, 6].
Key questions in all these studies were, whether the re-
spective physician had:
1. Withheld or withdrawn a probably life-prolonging
medical treatment taking into account or explicitly in-
tending hastening the patient's death, or
2. Intensified the alleviation of pain and/or symptoms
with drugs taking into account or partly intending
hastening the patient's death.
3. Prescribed or administered a drug with the explicit in-
tention of ending the patient's life (physician-assisted
death).
For cases in which more than one end-of-life practice was
reported, the most important end-of-life decision for this
case was, as in previous studies [2, 3], defined as the de-
cision with the most explicit intention concerning hasten-
ing death. If there was more than one decision with similar
intention concerning hastening death, question 3 prevailed
over question 2, and question 2 prevailed over question 1.
Structure
After some general questions (place of death, general prac-
titioner or specialist, broad cause of death group, cause of
death known since when, first contact with patient, "own"
patient yes or no) the questionnaire asked whether the death
had been sudden and unexpected. If answered negatively,
the case was regarded as eligible for an end-of-life decision
and the physician was asked the three key questions de-
Original article Swiss Med Wkly. 2016;146:w14307
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scribed above and whether the patient had given an ad-
vance care directive, or expressed a wish to hasten death or
to provide all possible life-prolonging measures. If any of
the three key questions was answered positively, further in-
formation referring to the most relevant life-shortening de-
cision was requested. In addition to an estimation of how
much life was shortened and which procedures were with-
held or withdrawn, the context of the decision-making pro-
cess was explored, including questions whether the physi-
cian discussed the relevant end-of-life practice and, in the
case of a positive answer, who initiated and who was in-
volved in the discussion; in the case of a negative answer,
the physician was asked what the reasons to abstain from
discussion were. With two additional questions the ability
of the patient to evaluate his or her situation and to make
an adequate decision was assessed. Eventually, the physi-
cian was asked which life-prolonging treatments were ap-
plied until the end of life and whether the patient had been
deeply and continuously sedated until death.
Definitions
If any of the three key questions was answered positively,
cases were categorised according to the most explicit life-
shortening intention into
(a) "forgoing life-prolonging treatment", if only key ques-
tion 1 (but not key question 2 or 3) was answered pos-
itively;
(b) "intensified alleviation of pain and/or symptoms", if
key question 2 – but not key question 3 – was
answered positively;
(c) "physician-assisted death", comprising the following
subcategories:
(c1) "assisted suicide", if key question 3 was answered
positively and the patient him/herself administered the
drug to end his/her life;
(c2) "euthanasia", if key question 3 was answered pos-
itively and not the patient, but somebody else ad-
ministered the drug AND the question regarding the
explicit request of the patient was answered in the af-
firmative;
(c3) "ending of life without the patients explicit re-
quest", if key question 3 was answered positively
AND the question regarding the explicit request of the
patient was NOT answered in the affirmative.
Data processing and analysis
Two rounds of plausibility checks were performed:
1. Determination of valid questionnaires (e.g., two
filled-in questionnaires with the same ID).
2. Elimination of inconsistencies (often with consulting
the original questionnaires).
All data from 2001 and 2013 were weighted to adjust for
age- and sex-specific differences in response rates. In addi-
tion, data from 2001 were age-standardised to the age dis-
tribution of the 2013 study sample (this may entail slight
differences from previously published figures). Final
weights varied between 0.54 and 1.42 in the 2001 survey,
and between 0.87 and 1.12 in the 2013 survey. Weighted
percentages, 95% confidence intervals (CIs) and p-values
for the comparison of 2001 and 2013 data were calculated
using the Pearson χ2 test for two-way contingency tables
(STATA 13.1 survey tables for weighted data; StataCorp
LP, College Station, TX).
Results
Based on all returned questionnaires, the weighted pro-
portion of nonsudden and expected deaths (principally eli-
gible for an end-of-life decision) was 69.9% (95% CI
68.3–71.4%) in 2001 and 71.4% (69.8–72.9%) in 2013.
Among eligible cases, the proportion of deaths preceded
by at least one end-of-life practice significantly increased
from 74.5% (72.7–76.3%) in 2001 to 82.3% (80.7–83.8%)
in 2013 (p <0.001, weighted cell counts 1747 vs 1863)
(table 1). There was no consistent sex/age pattern in either
the first or second survey (not shown in table). Most of
the increase was due to deaths in which forgoing life-pro-
longing treatment was the most important decision, with
41.1% (39.1–43.2%) of eligible deaths in 2001 and 49.3%
(47.3–51.4%) in 2013 (p <0.001, 964 vs 1117).
In contrast to forgoing life-prolonging treatment, the per-
centage of deaths that were preceded by intensified allevi-
ation of pain/symptoms as the most important end-of-life
decision remained almost stable – 32.0% (30.0–33.9%) in
2001 and 29.8% (28.0–31.7%) in 2013 (p = 0.12, 749 vs
675) – and so did the distribution of cases where life short-
ening was only taken into account / was partly intended.
Physician-assisted death (assisted suicide, euthanasia or
ending of life without the patient's explicit request) in-
creased from 1.4% (1.0–1.9%) in 2001 to 3.1% (2.5–3.9%)
in 2013 (p <0.001, 32 vs 71).
There were a substantial number of combinations of differ-
ent end-of-life decisions for one case (table 2 and fig. 1). In
fact, in more of half (51.2%) of all cases eligible for an end-
Figure 1
Overlap of different medical end-of-life practices, and categorisation
as most important practice, German-speaking part of Switzerland
2013. 100% = all nonsudden expected deaths (n = 2256). All
percentages are weighted. For categorisation as the most important
end-of-life practice, (a) plus (b) were categorised as forgoing life-
prolonging treatment, (c) plus (d) were categorised as intensified
alleviation of pain and symptoms (see also table 2); physician-
assisted death was always categorised as the most important
practice.
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of-life decision in 2013 there was forgoing of life-prolong-
ing treatment AND intensified alleviation of pain/symp-
toms in the same case. When cases in which this was not
the most important end-of-life decision were also included,
the prevalence of forgoing treatment rose from 41.1% to
59.9% in 2001 and from 49.3% to 70.0% in 2013. Simil-
arly, the total prevalence of intensified alleviation of pain/
symptoms rises from 32.0% to 51.8% in 2001 and from
29.8% to 63.4% in 2013.
There is also a remarkable pattern regarding the decision-
making capacity of the patient. The increase between 2001
and 2013 in the proportion of deaths preceded by at least
one end-of-life practice is roughly half attributable to each
of patients who were rated fully capable and patients who
were not rated regarding decision-making capacity by the
physician answering the questionnaire. Forgoing treatment
increased and intensified alleviation decreased in all cat-
egories of capability; however, most of those lacked full
capability (supplemental table S1; see appendix). In 2013,
the higher the capacity of the patient, the lower the propor-
tion of forgoing life-prolonging treatment and the higher
the proportion of intensified alleviation of pain/symptoms
and physician-assisted death.
Except for a slight shift from healthcare professionals to
other physicians, the proportions of involved persons in
2013 were almost identical to those in 2001 (table 3), with
either patient or relatives involved in 72.2% (70.1–74.2%)
of all deaths with mention of an end-of-life practice (2001:
70.3%, 68.0–72.4, p = 0.22, 1227 vs 1345).
In 2013, end-of-life issues were discussed with the patient
in 35.6% (33.4–37.8%) of all deaths with at least one re-
ported medical end-of-life practice. Prevalence of involve-
ment is strongly dependent on the patient's decision-mak-
ing capacity: end-of-life issues were discussed in 2013 with
73% of the fully capable patients, but only with 37% of
the not fully capable and 10% of the not at all capable pa-
tients (table 4). Generally, there is a tendency to increased
involvement of patients, with, nevertheless, one striking
exception: among patients with full capacity, the preval-
ence of end-of-life practices discussed with the patient de-
creased from 79.0% (75.3–82.3%) in 2001 to 73.2%
(69.6–76.0%) in 2013 (p = 0.037, 432 vs 459).
When discussion with relatives and otherwise expressed
preferences of the patient were also taken into account,
76.5% (74.5–78.4%) of all cases with reported medical
end-of-life practice in 2013 relied on shared decision-mak-
ing, varying from 79.8% (76.5–82.7%) among the not at all
capable patients to 87.8% (85.0–90.2%) among fully cap-
able patients. Whereas for the former this implies a signi-
ficant increase compared with 2001 (72.7%, p <0.003, 487
vs 517), there is still a slight but insignificant decrease for
the latter (2001: 89.1%, p = 0.51, 487 vs 550).
Discussion
In the German-speaking part of Switzerland in 2013, more
than four of five nonsudden deaths were preceded by at
least one end-of-life practice. The prevalence of deaths
with at least one reported end-of-life practice significantly
increased from 52.0% of all deaths in 2001 to 58.7% in
2013 [7], from 74.5% to 82.3%, respectively, of all deaths
eligible for an end-of-life practice. This increase is in line
with trends in the Netherlands (43.8% of all deaths in 2001
and 57.8% in 2010)[5] and in Belgium (38.4% in 2001 and
47.8% in 2013)[6].
Table 1: Prevalence of medical end-of-life practices* in the German-speaking part of Switzerland, 2001 vs 2013 (100% = all non-sudden expected deaths; percentages
weighted and standardized to 2013 deaths).
* If more than one end-of-life practice was reported, the most explicit regarding life-shortening was decisive for classification.
Nonsudden expected deaths
(eligible for end-of-life decision)
2001
(n = 2281)
2013
(n = 2256)
Trend
Percentage (95% CI) Percentage (95% CI) p-value (weighted cell counts
2001, 2013)
No end-of-life practice 25.5% (23.7–27.4) 17.7% (16.2–19.3) <0.001 (598.4, 400.8)
With end-of-life practice 74.5% (72.7–76.3) 82.3% (80.7–83.8) <0.001 (1746, 1863)
Forgoing life-prolonging treatment 41.1% (39.1–43.2) 49.3% (47.3–51.4) <0.001 (964.4, 1117)
Taking into account hastening of death1 10.5% (9.3–11.9) 6.4% (5.4–7.5) <0.001 (246.5, 144.2)
Intending hastening of death2 30.6% (28.7–32.6) 43.0% (40.9–45.0) <0.001 (717.9, 973.1)
Intensified alleviation of pain/symptoms 32.0% (30.0–33.9) 29.8% (28.0–31.7) 0.121 (749.3, 675.1)
Taking into account hastening of death3 28.4% (26.5–30.3) 26.9% (25.1–28.8) 0.270 (664.9, 608.6)
Partly intending hastening of death4 3.6% (2.9–4.5) 2.9% (2.3–3.7) 0.207 (84.5, 66.5)
Physician-assisted death 1.4% (1.0–1.9) 3.1% (2.5–3.9) <0.001 (32.4, 70.9)
Assisted suicide5 0.4% (0.2–0.7) 1.6% (1.1–2.2) <0.001 (9.7, 35.3)
Euthanasia6 0.3% (0.2–0.7) 0.5% (0.3–0.8) 0.438 (7.7, 10.6)
Ending of life without the patient's explicit request7 0.6% (0.4–1.1) 1.1% (0.7–1.6) 0.095 (15.0, 25.0)
1 Affirmative answer to the question, “Did you or another physician withhold or withdraw a medical treatment while taking into account the possible hastening of death?”
2 Affirmative answer to the question, “Did you or another physician withhold or withdraw a medical treatment with the intention to hasten death?”
3 Affirmative answer to the question, “Did you or another physician intensify the alleviation of pain and/or symptoms while taking into account the possible hastening of
death?”
4 Affirmative answer to the question, “Did you or another physician intensify the alleviation of pain and/or symptoms partly with the intention to hasten death?”
5 Affirmative answer to the question, “Was death the consequence of the use of a drug that was prescribed or supplied by you or another physician with the explicit
intention of enabling the patient to end his or her life?”
6 Affirmative answer to the question, “Was death the consequence of the use of a drug that was prescribed or supplied by you or another physician with the explicit
intention of hastening the patient's death?” AND affirmative answer to the question: "Was this decision made at the explicit request of the patient?"
7 Affirmative answer to the question, “Was death the consequence of the use of a drug that was prescribed or supplied by you or another physician with the explicit
intention of hastening the patient's death?” AND no affirmative answer to the question: "Was this decision made at the explicit request of the patient?
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In Switzerland, most of this increase is due to forgoing life-
prolonging treatment as the most important end-of-life de-
cision. The prevalence of this practice was already in 2001
one of the highest in Europe [2] and the increase since then
contrasts to the situation in other countries, where only a
modest increase (Belgium, [6]) or even a slight decrease
(the Netherlands, [5]) was observed.
The prevalence of intensified alleviation of pain/symptoms
as the most important end-of-life decision in relation to
all deaths was in 2001 similar to that in Belgium and the
Netherlands [2], and in relation to all deaths with end-of-
life decisions was even clearly lower. The slight decrease
between 2001 and 2013 is at variance with an increase in
Belgium [6] and an even more pronounced increase in the
Netherlands [5].
However, the in-depth analysis presented in this paper re-
vealed that in fact there was in Switzerland also an increase
of intensified alleviation of pain/symptoms in this period.
This increase does not become obvious in a unidimensional
categorisation according to the most important end-of-life
decision, as Swiss physicians in 2013 much more often
than in 2001 attributed an intention of hastening death to
their decision to forgo life-prolonging treatment, meaning
that those “intended forgoing treatment decisions” very of-
ten overruled an intensified alleviation of pain/symptoms.
This seems to point to an increasingly complex interweav-
ing of different end-of-life decisions in modern medical
Table 2: Forgoing life-prolonging treatment and intensified alleviation of pain and symptoms, German-speaking part of Switzerland 2001 vs 2013 (100% = all nonsudden
expected deaths; percentages weighted and standardized to 2013 deaths).
Nonsudden expected deaths
(eligible for end-of-life decision)
2001
n = 2281
2013
n = 2256
Trend
Percentage (95% CI) Percentage (95% CI) p-value (weighted cell counts
2001, 2013)
Forgoing life-prolonging treatment
Total 59.9% (57.8–61.9) 70.0% (68.1–71.9) <0.001 (1403, 1585)
Life-shortening accepted 28.6% (26.8–30.6) 25.8% (24.0–27.6) 0.033 (671.1, 583.7)
Life-shortening intended 31.2% (29.3–33.2) 44.2% (42.2–46.3) <0.001 (732, 1001)
Not combined with other medical end-of-life practice (a) 22.4% (20.7–24.2) 17.3% (15.8–18.9) <0.001 (525, 392.1)
Combined with intensified alleviation of pain/symptoms only 36.6% (34.6–38.7) 51.2% (49.1–53.2) <0.001 (858.6, 1158)
- Ditto, only intended forgoing of treatment (b) 18.7% (17.2–20.4) 32.0% (30.1–34.0) <0.001 (439.4, 725.2)
Combined with physician-assisted death 0.8% (0.5–1.3) 1.5% (1.1–2.1) 0.030 (19.5, 34.6)
Intensified alleviation of pain/symptoms
Total 51.8% (49.7–53.8) 63.4% (56.0–58.9) <0.001 (1213, 1435)
Life shortening accepted 41.1% (39.1–43.2) 51.7% (49.7–53.8) <0.001 (963.8, 1172)
Life-shortening partly intended 10.6% (9.4–12.0) 11.6% (10.5–13.0) 0.294 (249.5, 263.3)
Not combined with other medical end-of-life practice (c) 14.1% (12.7–15.6) 10.7% (9.5–12.0) <0.001 (330.1, 241.9)
Combined with forgoing life-prolonging treatment only 36.6% (34.6–38.7) 51.2% (49.1–53.2) <0.001 (858.6, 1158)
- Ditto, only unintended forgoing of treatment (d) 17.9% (16.3–19.5) 19.1% (17.6–20.8) 0.281 (419.2, 433.2)
Combined with physician-assisted death 1.0% (0.7–1.6) 1.5% (1.0–1.7) 0.150 (24.5, 34.5)
Forgoing life-prolonging treatment as most explicit end-of-life decision (cf. table 1): (a) + (b)
Intensified alleviation of pain/symptoms as most explicit end-of-life decision (cf. table 1): (c) + (d)
(see also fig. 1)
Table 3: Persons involved in medical end-of-life decisions, German-speaking part of Switzerland 2001 vs 2013 (multiple answers allowed). (100% = all deaths with
reported end-of-life practice; percentages weighted and standardised to 2013 deaths).
Deaths with end-of-life practice mentioned
(eligible for involvement)
2001
n = 1704
2013
n = 1856
Trend
Percentage
(95% CI)
Percentage
(95% CI)
p-value (weighted cell counts
2001, 2013)
No information about involved persons1 6.3% (5.2–7.5) 10.3% (9.0–11.8) <0.001 (109.1, 192)
Not discussed2 10.9% (9.4–12.5) 7.5% (6.4–8.8) <0.001 (190.8, 140.2)
Discussion with patient3 34.1% (31.9–36.4) 35.6% (33.4–37.8) <0.001 (595.6, 662.9)
Relatives involved4 64.5% (62.2–66.8) 66.1% (63.9–68.2) <0.001 (1127, 1231)
Patient or relatives involved 70.3% (68.0–72.4) 72.2% (70.1–74.2) 0.218 (1227, 1345)
Patient and relatives involved 28.4% (26.3–30.6) 29.5% (27.4–31.6) 0.466 (495.4, 549.5)
Other physician(s) involved5 35.4% (33.2–37.7) 48.0% (45.7–50.3) <0.001 (618.4, 894.1)
Healthcare professionals involved6 51.6% (49.2–54.1) 41.4% (39.2–43.7) <0.001 (901.9, 772.4)
Other person(s) involved7 4.4% (3.5–5.5) 2.1% (1.6–2.9) <0.001 (76.3, 39.7)
1 None of the two respective questions answered
2 Both respective questions answered with "no"
3 Affirmative answer to the question, “Did you or another physician discuss the end-of-life practice and the potential hastening of death with the patient?”
4 Affirmative answer to the question, “Did you or another physician discuss the end-of-life practice and the potential hastening of death with one or more relatives of the
patient?”
5 Affirmative answer to the question, “Did you or another physician discuss the end-of-life practice and the potential hastening of death with one or more physicians?”
6 Affirmative answer to the question, “Did you or another physician discuss the end-of-life practice and the potential hastening of death with one or more health care
professionals?”
7 Affirmative answer to the question, “Did you or another physician discuss the end-of-life practice and the potential hastening of death with somebody else?”
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end-of-life practice, making it more difficult to attach a
particular end-of-life decision as the most important one to
a specific patient.
In our 2013 study, only a small minority of end-of-life
decisions were not discussed by the involved physician
(8.4%, if missing answers on the respective questions were
rated as random failure and 17.8% if they were defined as
"not discussed"). In the 2001 survey (German) Switzerland
already scored well in this respect [2] and between the two
surveys involvement of patients even increased, but rather
modestly in view of the increase in health literacy and the
paradigmatic change from paternalistic to shared decision-
making that occurred in the past decades [12, 13].
Excluding records with unknown patient's capacity, in at
least 80% of cases medical end-of-life discussions in 2013,
the patient him/herself or his/her relatives were involved or
the patient's preferences were already known to the physi-
cian, with only modest variation between categories of pa-
tient's decision-making capacity.
Within a general tendency to increasing shared decision-
making between 2001 and 2013, the decreased incidence of
discussion with fully capable patients from 79.0% to 73.2%
(borderline significance) is striking. Including all kinds of
patient's involvement (relatives, otherwise known preferen-
ces), the decrease (89.1% vs 87.8%) is insignificant.
Nevertheless, one might ask why not all fully capable pa-
tients were involved in decision-making. Comparing fully
capable patients with and without involvement revealed
only a few differences. "Obviously in the interest of the
patient" as reason for not having discussed decision-mak-
ing was mentioned in 2013 for three out of ten cases with
no discussion. However, this answer was even more fre-
quent in 2001. A more remarkable difference concerns the
type of most important end-of-life procedure, since the pro-
portions forgoing a treatment and intensified alleviation of
pain/symptoms were exactly inverted among those with no
involvement (2013: 33.4% forgoing treatment vs 65.2% al-
leviation). One might assume that this is due to a differ-
ent distribution according to causes of death, with cancer
patients needing more alleviation. However, the respective
variation is far too small to explain the described differen-
ce. One might, therefore, speculate that forgoing treatment
was rated by capable patients as more relevant than intens-
ified alleviation and that the latter was understood as pal-
liative or even comfort therapy in order to increase quality
of life and, therefore, not equally important to be discussed.
Another explanation may be that end-of-life decision dis-
cussions are demanding and there are many obstacles to
a good conversation, especially indisposition of the phys-
ician or unwillingness of the patient or the family to con-
sider the approach of death [14].
The relatively high proportion with intensified alleviation
of pain/symptoms among fully capable patients might be
due to a better ability among these patients to describe
their symptoms and to draw upon customised treatment
schemes, e.g. for pain, dyspnoea, nausea or restlessness.
Another reason may be cancer patients: they are younger
and more prevalent among the fully capable, and generally
they often need alleviation of pain [15].
It also cannot be ruled out that in some cases end-of-life
discussion was planned, but outpaced by death or unexpec-
ted loss of decision-making capacity. Unfortunately these
issues were not included in the predefined answers to the
question about reasons for forgoing discussion with the pa-
tient. Findings of an Australian study, where 77% of in-
patients had their first documented end-of-life discussion
only 3 days before death [16], as well as of a Dutch study,
where the proportion of people with limited decision-mak-
ing capacity increased from 27% 1 month before death to
67% in the last week of life [17] support the notion that dis-
cussion could be missed more often than might be expec-
ted.
Strengths and limitations
Given the voluntary nature of the survey, independent of
reporting duties or changing legislative background, the re-
sponse rates (63.5% in 2013, 67.2% in 2001) in German-
speaking Switzerland are remarkably high and only slightly
lower than in the Netherlands (75% in 2001 [2], 74% in
2010 [5]). The substantial sample of deaths can, therefore,
be seen as representative for all deaths in all settings in
German-speaking Switzerland, allowing valid comparisons
between 2001 and 2013. Although the optimal phrasing of
the questionnaire is the subject of a continuing controversy
[18, 19], it is widely accepted that this kind of study is
still the gold standard for assessing medical end-of-life de-
cisions on a population level.
Table 4: Discussion of medical end-of-life decisions in function of the patient's decision-making capacity, German-speaking part of Switzerland 2001 vs 2013. (100% = all
deaths with reported end-of-life practice; percentages weighted and standardized to 2013 deaths).
Deaths with end-of-life practice mentioned
(eligible for involvement)
2001
n = 1704
2013
n = 1856
Trend
Percentage (95% CI) Percentage (95% CI) p-value (weighted cell counts
2001, 2013)
Discussed with patient3 34.1% (31.9–36.4) 35.6% (33.4–37.8) <0.001 (595.6, 662.9)
Patient fully capable 79.0% (75.3–82.3) 73.2% (69.6–76.0) 0.037 (432.1, 458.7)
Patient not fully capable 32.4% (27.7–37.6) 37.1% (32.2–42.3) 0.196 (116.9, 133.7)
Patient not capable at all 6.7% (5.0–8.9) 9.7% (7.6–12.2) 0.051 (44.71, 62.77)
Patient's capability unknown 1.2% (0.3–4.5) 3.4% (0.2–6.7) <0.001 (1.94, 7.75)
Discussed with patient and/or relatives and/or patient ever
expressed wish
74.4% (72.2–76.5) 76.5% (74.5–78.4) 0.138 (1297, 1425)
Patient fully capable 89.1% (86.1–91.5) 87.8% (85.0–90.2) 0.508 (487.2, 550)
Patient not fully capable 80.1% (75.5–84.0) 85.3% (81.2–88.6) 0.073 (288.6, 307)
Patient not capable at all 72.7% (69.0–76.1) 79.8% (76.5–82.7) 0.003 (486.8, 517.3)
Patient's capability unknown 21.6% (15.8–28.9) 22.1% (17.2–28.0) 0.910 (36.6, 50.6)
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This study has several limitations. All information is de-
rived from physicians' reports, and is thus dependent on the
physicians' assessment of the situation – which is, however,
most appropriate for the physician's intention and therefore
medical end-of-life practices. However, we do not know
the contents and outcome of the discussions between phys-
icians and patients, relatives and other caregivers, a know-
ledge relevant to developing standards [4]. We also cannot
exclude the possibility of a nonresponse bias, all the more
as an affirmative answer to question 6 "Was death sudden
and unexpected" offered an easy option to skip all poten-
tially sensitive questions. While we cannot test this, we
found indications supporting the finding of Fischer et al.
that in the 2001 survey nonresponders had significantly
fewer terminal patients than responders [20]: among cancer
patients, who make up a stratum with higher likelihood
of an end-of-life decision, in our study response was also
higher. This probably also applies to the responding physi-
cians' personal interest in and attitudes towards end-of-life
issues. As a consequence, prevalence rates might be over-
estimated, but should not bias either the relative differences
between subgroups or the comparison of 2001 and 2013.
Conclusion
In our Swiss study population, incidence of end-of-life de-
cisions in general and of shared decision-making in partic-
ular was remarkably high. There was increasingly a variety
of different end-of-life practices interweaved in one pa-
tient. A deeper understanding of the frequency of medical
end-of-life decisions requires analysis of this pattern, e.g.,
including combinations, rather than just focussing on the
construction of a "most important end-of-life decision“ in a
particular case.
In general, there is a high level of involvement of patients
and relatives in the decision-making process. Nevertheless
there remains potential for improvement, since cases
without intelligible explanation for missing discussion still
do not seem to be rare exceptions. It may, therefore, be use-
ful to analyse social disparities, for example educational
level, which have been shown to entail an unequal use of
palliative care [21].
It is also known that among physicians there still exist
obstacles to addressing end-of-life issues [14]. More sus-
tained efforts to increase motivation may, therefore, be in-
dicated in order to increase certainty of optimal decisions
and the satisfaction of relatives [8].
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Appendix
Supplementary table
Table S1: Medical end-of-life decisions* by level of patient's decision-making capacity, German-speaking part of Switzerland 2001 vs 2013. (100% = all deaths with
reported end-of-life practice; percentages weighted and standardized to 2013 deaths).
* If more than one end-of-life practice was reported, the most explicit regarding life-shortening was decisive for classification.
Deaths with end-of-life practice mentioned
(eligible for involvement)
2001
n = 1704
2013
n = 1856
Trend
Percentage (95% CI) Percentage (95% CI) p-value (weighted cell counts
2001, 2013)
Patient rated as fully capable n = 548 (100%) n = 625 (100%)
Forgoing life-prolonging treatment 53.8% (49.6–58.1) 59.4% (55.4–63.1) 0.060 (294.4, 371.7)
Intensified alleviation of pain/symptoms 42.6% (38.4–46.8) 36.4% (32.7–40.3) 0.034 (232.9, 228.3 )
Physician-assisted death 3.6% (2.3–5.5) 4.2% (2.9–6.1) 0.579 (19.6, 26.3)
Patient rated as not fully capable n = 348 (100%) n = 357 (100%)
Forgoing life-prolonging treatment 51.6% (46.3–56.9) 62.0% (56.8–66.9) 0.006 (186, 223.1)
Intensified alleviation of pain/symptoms 47.3% (42.0–52.6) 35.8% (31.0–40.9) 0.002 (170.3, 128.8)
Physician-assisted death 1.1% (0.5–2.8) 2.2% (1.1–4.4) 0.231 (4.1, 8.1)
Patient rated as not at all capable n = 641 (100%) n = 644 (100%)
Forgoing life-prolonging treatment 65.3% (61.5–69.0) 69.9% (66.6–73.3) 0.083 (437.4, 453.3)
Intensified alleviation of pain/symptoms 34.2% (30.5–38.0) 28.5% (25.2–32.2) 0.032 (228.7, 185.1)
Physician-assisted death 0.5% (0.2–1.6) 1.6% (0.8–2.9) 0.078 (3.5, 10.1)
Patient's capability not rated1 n = 167 (100%) n = 230 (100%)
Forgoing life-prolonging treatment 27.5% (21.0–35.0) 30.3% (24.6–36.6) 0.558 (46.5, 69.2)
Intensified alleviation of pain/symptoms 69.4% (61.8–76.1) 58.2% (51.6–64.4) 0.025 (117.5, 133)
Physician-assisted death 3.1% (1.4–6.8) 11.6% (8.0–16.4) 0.001 (5.2, 26.5)
1 Neither of the two respective questions answered
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Figures (large format)
Figure 1
Overlap of different medical end-of-life practices, and categorisation as most important practice, German-speaking part of Switzerland 2013.
100% = all nonsudden expected deaths (n = 2256). All percentages are weighted. For categorisation as the most important end-of-life practice,
(a) plus (b) were categorised as forgoing life-prolonging treatment, (c) plus (d) were categorised as intensified alleviation of pain and symptoms
(see also table 2); physician-assisted death was always categorised as the most important practice.
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